source
- OKYO Pharma CSO Raj Patil boosts stake to 20,030 sharesOKYO Pharma, a clinical stage biotech focused on neuropathic corneal pain and anterior segment eye diseases, disclosed that its chief scientific officer, Raj Patil, PhD, bought additional shares.…
- Experts discuss when to start therapy for pediatric low‑grade glioma, weighing chemo, MEK inhibitors and family factorsIn a recent discussion, pediatric neuro‑oncologists examined how to decide when to begin treatment for low‑grade glioma in children. They highlighted the need to balance chemotherapy and MEK inhibi…